PURI Puricore

TIDMRLM

Realm Therapeutics PLC

07 September 2017

Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")

Realm Therapeutics to present at the Rodman & Renshaw 19th Annual Global Investment Conference

7 September 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the Rodman & Renshaw 19(th) Annual Global Investment Conference on Tuesday, 12 September at 1:45 PM at the Lotte New York Palace Hotel in New York, NY.

Mr. Martin will review the Company's two lead drug development programs - PR022 for Atopic Dermatitis and PR013 for Allergic Conjunctivitis (AC). Realm recently announced submission of its second investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for PR013, as a novel treatment for AC. Pending clearance, the IND will enable Realm to initiate a Phase II trial for patients aged 10 years and older by the end of the year. Additionally, the Company remains on track to commence a Phase II trial for PR022 later this year.

Enquiries:

 
                                         +44 (0) 20 3727 
 Realm Therapeutics plc                   1000 
 Alex Martin, Chief Executive Officer 
 Marella Thorell, Chief Financial 
  Officer and Chief Operating Officer 
 
                                         +44 (0) 20 3727 
 FTI Consulting                           1000 
 Simon Conway / Mo Noonan 
 
 N+1 Singer (Nominated Adviser and       +44 (0) 20 7496 
  Broker)                                 3000 
 Aubrey Powell / Lauren Kettle 
 

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.

Forward looking statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUNVVRBOAKRAR

(END) Dow Jones Newswires

September 07, 2017 02:01 ET (06:01 GMT)

Puricore (LSE:PURI)
Historical Stock Chart
From Dec 2024 to Jan 2025

Puricore (LSE:PURI)
Historical Stock Chart
From Jan 2024 to Jan 2025